These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

436 related items for PubMed ID: 16359375

  • 1. Use of anti-HBc positive allografts in adult liver transplantation: toward a safer way to expand the donor pool.
    Donataccio D, Roggen F, De Reyck C, Verbaandert C, Bodeus M, Lerut J.
    Transpl Int; 2006 Jan; 19(1):38-43. PubMed ID: 16359375
    [Abstract] [Full Text] [Related]

  • 2. De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population.
    Prieto M, Gómez MD, Berenguer M, Córdoba J, Rayón JM, Pastor M, García-Herola A, Nicolás D, Carrasco D, Orbis JF, Mir J, Berenguer J.
    Liver Transpl; 2001 Jan; 7(1):51-8. PubMed ID: 11150423
    [Abstract] [Full Text] [Related]

  • 3. Transmission of hepatitis B infection from hepatitis B core antibody--positive liver allografts is prevented by lamivudine therapy.
    Yu AS, Vierling JM, Colquhoun SD, Arnaout WS, Chan CK, Khanafshar E, Geller SA, Nichols WS, Fong TL.
    Liver Transpl; 2001 Jun; 7(6):513-7. PubMed ID: 11443579
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Liver transplantation with allografts from hepatitis B core antibody-positive donors: a new approach.
    Fábrega E, García-Suarez C, Guerra A, Orive A, Casafont F, Crespo J, Pons-Romero F.
    Liver Transpl; 2003 Sep; 9(9):916-20. PubMed ID: 12942452
    [Abstract] [Full Text] [Related]

  • 10. Risk of transmission of hepatitis B virus from anti-HBC positive cadaveric organ donors: a collaborative study.
    De Feo TM, Poli F, Mozzi F, Moretti MP, Scalamogna M, Collaborative Kidney, Liver and Heart North Italy Transplant Program Study Groups.
    Transplant Proc; 2005 Mar; 37(2):1238-9. PubMed ID: 15848681
    [Abstract] [Full Text] [Related]

  • 11. Occult hepatitis B virus infection in HBsAg negative patients undergoing liver transplantation: clinical significance.
    Ghisetti V, Marzano A, Zamboni F, Barbui A, Franchello A, Gaia S, Marchiaro G, Salizzoni M, Rizzetto M.
    Liver Transpl; 2004 Mar; 10(3):356-62. PubMed ID: 15004761
    [Abstract] [Full Text] [Related]

  • 12. Lamivudine monoprophylaxis for de novo HBV infection in HBsAg-negative recipients with HBcAb-positive liver grafts.
    Vizzini G, Gruttadauria S, Volpes R, D'Antoni A, Pietrosi G, Filì D, Petridis I, Pagano D, Tuzzolino F, Santonocito MM, Gridelli B.
    Clin Transplant; 2011 Mar; 25(1):E77-81. PubMed ID: 21039887
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Survival after orthotopic liver transplantation: the impact of antibody against hepatitis B core antigen in the donor.
    Yu L, Koepsell T, Manhart L, Ioannou G.
    Liver Transpl; 2009 Oct; 15(10):1343-50. PubMed ID: 19790164
    [Abstract] [Full Text] [Related]

  • 15. Change of hepatitis B virus DNA status in anti-HBc positive liver graft.
    Kwon CH, Suh KS, Cho JY, Yi NJ, Jang JJ, Lee KU.
    Korean J Hepatol; 2006 Jun; 12(2):191-200. PubMed ID: 16804344
    [Abstract] [Full Text] [Related]

  • 16. Hepatitis B virus infection in allogeneic bone marrow transplantation.
    Ustün C, Koç H, Karayalcin S, Akyol G, Gürman G, Ilhan O, Akan H, Ozcan M, Arslan O, Konuk N, Uysal A, Beksaç M.
    Bone Marrow Transplant; 1997 Aug; 20(4):289-96. PubMed ID: 9285543
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Lamivudine prophylaxis and treatment of hepatitis B Virus-exposed recipients receiving reduced intensity conditioning hematopoietic stem cell transplants with alemtuzumab.
    Moses SE, Lim ZY, Sudhanva M, Devereux S, Ho AY, Pagliuca A, Zuckerman M, Mufti GJ.
    J Med Virol; 2006 Dec; 78(12):1560-3. PubMed ID: 17063522
    [Abstract] [Full Text] [Related]

  • 19. Ten-year follow-up of kidney transplantation from hepatitis B surface antigen-positive donors.
    Sumethkul V, Ingsathit A, Jirasiritham S.
    Transplant Proc; 2009 Dec; 41(1):213-5. PubMed ID: 19249516
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.